- Home
- UMAC vs ACRV Comparison
UMAC vs ACRV Comparison
Compare UMAC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UMAC
- ACRV
- Stock Information
- Founded
- UMAC 2019
- ACRV 2018
- Country
- UMAC United States
- ACRV United States
- Employees
- UMAC N/A
- ACRV N/A
- Industry
- UMAC
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- UMAC
- ACRV Health Care
- Exchange
- UMAC Nasdaq
- ACRV Nasdaq
- Market Cap
- UMAC 165.6M
- ACRV 170.3M
- IPO Year
- UMAC 2024
- ACRV 2022
- Fundamental
- Price
- UMAC $12.95
- ACRV $5.78
- Analyst Decision
- UMAC Strong Buy
- ACRV Strong Buy
- Analyst Count
- UMAC 2
- ACRV 5
- Target Price
- UMAC $11.00
- ACRV $22.40
- AVG Volume (30 Days)
- UMAC 3.4M
- ACRV 52.8K
- Earning Date
- UMAC 02-20-2025
- ACRV 11-13-2024
- Dividend Yield
- UMAC N/A
- ACRV N/A
- EPS Growth
- UMAC N/A
- ACRV N/A
- EPS
- UMAC N/A
- ACRV N/A
- Revenue
- UMAC $3,561,303.00
- ACRV N/A
- Revenue This Year
- UMAC N/A
- ACRV N/A
- Revenue Next Year
- UMAC $66.18
- ACRV N/A
- P/E Ratio
- UMAC N/A
- ACRV N/A
- Revenue Growth
- UMAC N/A
- ACRV N/A
- 52 Week Low
- UMAC $0.98
- ACRV $3.19
- 52 Week High
- UMAC $23.62
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- UMAC 50.74
- ACRV 43.36
- Support Level
- UMAC $12.27
- ACRV $5.36
- Resistance Level
- UMAC $13.97
- ACRV $6.00
- Average True Range (ATR)
- UMAC 2.29
- ACRV 0.54
- MACD
- UMAC -0.63
- ACRV -0.02
- Stochastic Oscillator
- UMAC 19.81
- ACRV 24.73
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is a development stage technology company.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.